KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Dec 2024 value amounting to -$372.9 million.

  • Recursion Pharmaceuticals' Free Cash Flow fell 84.37% to -$117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.7 million, marking a year-over-year decrease of 34.73%. This contributed to the annual value of -$372.9 million for FY2024, which is 24.40% down from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Free Cash Flow is -$372.9 million, which was down 24.40% from -$299.7 million recorded in FY2023.
  • Recursion Pharmaceuticals' Free Cash Flow's 5-year high stood at -$51.2 million during FY2020, with a 5-year trough of -$372.9 million in FY2024.
  • For the 3-year period, Recursion Pharmaceuticals' Free Cash Flow averaged around -$264.4 million, with its median value being -$299.7 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Free Cash Flow tumbled by 287.30% in 2021 and then surged by 39.23% in 2022.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Free Cash Flow stood at -$51.2 million in 2020, then crashed by 287.30% to -$198.4 million in 2021, then skyrocketed by 39.23% to -$120.6 million in 2022, then slumped by 148.57% to -$299.7 million in 2023, then fell by 24.40% to -$372.9 million in 2024.